GFS Advisors’s Bristol-Myers Squibb BMY Stock Holding History

GFS Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.6K	Sell	26,710 -265	-1%	-$15.2K	﹤0.01%	231
2026 Q1	$1.64M	Buy	26,975 +165	+0.6%	+$9.62K	0.21%	78
2025 Q4	$1.45M	Buy	+26,810	New	+$1.29M	0.17%	88
2023 Q4	–	Sell	-12,850	Closed	-$746K	–	153
2023 Q3	$746K	Buy	+12,850	New	+$787K	0.12%	108
2020 Q2	–	Sell	-6,030	Closed	-$336K	–	120
2020 Q1	$336K	Sell	6,030 -100	-2%	-$6.11K	0.1%	92
2019 Q4	$393K	Buy	6,130 +100	+2%	+$5.73K	0.1%	100
2019 Q3	$306K	Hold	6,030	–	–	0.09%	104
2019 Q2	$273K	Hold	6,030	–	–	0.08%	106
2019 Q1	$288K	Sell	6,030 -210	-3%	-$10.5K	0.09%	99
2018 Q4	$324K	Buy	6,240 +2,330	+60%	+$125K	0.09%	96
2018 Q3	$243K	Hold	3,910	–	–	0.06%	117
2018 Q2	$216K	Hold	3,910	–	–	0.04%	137
2018 Q1	$259K	Sell	3,910 -13	-0.3%	-$836	0.05%	128
2017 Q4	$240K	Sell	3,923 -888	-18%	-$55.5K	0.05%	131
2017 Q3	$307K	Sell	4,811 -223	-4%	-$13K	0.07%	128
2017 Q2	$280K	Hold	5,034	–	–	0.06%	134
2017 Q1	$274K	Buy	+5,034	New	+$276K	0.06%	132

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GFS Advisors's BMY Position: Q2 2026 in Review

GFS Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.98% in Q2 2026, selling an estimated $15.2K and leaving 26,710 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #231.

GFS Advisors first reported a position in BMY in Q1 2017 and has held it in 17 quarters since. The position peaked at $1.64M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

GFS Advisors held 26,710 shares of Bristol-Myers Squibb worth $18.6K as of Q2 2026.
GFS Advisors sold 265 Bristol-Myers Squibb shares in Q2 2026, an estimated $15.2K.
Bristol-Myers Squibb made up ﹤0.01% of GFS Advisors's portfolio in Q2 2026, its #231 holding.
GFS Advisors first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 17 quarters since.
GFS Advisors's Bristol-Myers Squibb position peaked at $1.64M in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on GFS Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.